Also trades as: LITS (NASDAQ) · $vol 0M
0JW9.L LSE
Lite Strategy, Inc.
1W: -7.6%
1M: -8.4%
3M: -20.4%
YTD: +3.8%
1Y: -65.3%
$1.08
+0.00 (+0.00%)
Weekly Expected Move ±6.0%
$1
$1
$1
$1
$1
Overview
News
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market Cap$7.2M
52W Range1.06-7.85848
Volume2,468
Avg Volume400
Beta0.20
Dividend—
Analyst Ratings
Company Info
CEOJustin J. File
Employees28
SectorFinancial Services
IndustryAsset Management - Cryptocurrency
IPO Date2018-01-29
Websitelitestrategy.com
11455 El Camino Real
San Diego, CA 92130
US
San Diego, CA 92130
US
858 369 7100
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. It also engages in digital asset treasury management. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Latest News
No recent news
Recent Insider Trades
No insider trades found